We present real-world data on all ruxolitinib treated myelofibrosis patients in a 10-million resident region, with a follow-up of 2 years. We found no evidence of an increased risk of developing lymphomas.

Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.

Rumi E;Cavalloni C;
2019-01-01

Abstract

We present real-world data on all ruxolitinib treated myelofibrosis patients in a 10-million resident region, with a follow-up of 2 years. We found no evidence of an increased risk of developing lymphomas.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11571/1321967
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 19
social impact